Five (Non-COVID) Clinical Trial Misses Of 2021
Executive Summary
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
You may also be interested in...
Sandrock Joins Voyager As CEO To Advance New Gene Therapy Technology Into The Clinic
The former Biogen executive will succeed interim CEO Michael Higgins, who will continue as chairman.
New Player Joins Search For Effective Huntington's Therapies
Despite recent setbacks for Roche and Wave's respective antisense offerings, both those two firms and a number of other companies are trying a variety of approaches to find a treatment for Huntington's.
Novartis Hopes For Canakinumab In Lung Cancer Nosedive
After deciding to examine canakinumab's potential in lung cancer on the back of the CANTOS cardiovascular trial, Novartis designed a major late-stage program in oncology for the interleukin-1 beta inhibitor. The second of those CANOPY trials has just come crashing down.